Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases.
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Evoke Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EVOK has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: EVOK underperformed the US Pharmaceuticals industry which returned 6.3% over the past year.
Return vs Market: EVOK underperformed the US Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is Evoke Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StWill Evoke Pharma (NASDAQ:EVOK) Spend Its Cash Wisely?
2 months ago | Simply Wall StDoes The Evoke Pharma, Inc. (NASDAQ:EVOK) Share Price Tend To Follow The Market?
3 months ago | Simply Wall StWhat Kind Of Shareholder Owns Most Evoke Pharma, Inc. (NASDAQ:EVOK) Stock?
Is Evoke Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate EVOK's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate EVOK's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: EVOK is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: EVOK is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EVOK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EVOK is overvalued based on its PB Ratio (7.1x) compared to the US Pharmaceuticals industry average (3x).
How is Evoke Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EVOK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EVOK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EVOK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if EVOK's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if EVOK's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EVOK's Return on Equity is forecast to be high in 3 years time
How has Evoke Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EVOK is currently unprofitable.
Growing Profit Margin: EVOK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EVOK is unprofitable, but has reduced losses over the past 5 years at a rate of 11.7% per year.
Accelerating Growth: Unable to compare EVOK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EVOK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.4%).
Return on Equity
High ROE: EVOK has a negative Return on Equity (-144.36%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Evoke Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: EVOK's short term assets ($7.3M) exceed its short term liabilities ($2.2M).
Long Term Liabilities: EVOK has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: EVOK is debt free.
Reducing Debt: EVOK has no debt compared to 5 years ago when its debt to equity ratio was 0.4%.
Inventory Level: EVOK has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if EVOK's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EVOK has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: EVOK has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of -0% each year.
What is Evoke Pharma's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate EVOK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate EVOK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EVOK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EVOK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EVOK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dave Gonyer (55yo)
Mr. David A. Gonyer, also known as Dave, R.Ph., is a Co-Founder of Evoke Pharma, Inc. and has been its Chief Executive Officer and President since March 2007. Mr. Gonyer held senior management positions bo ...
CEO Compensation Analysis
Compensation vs Market: Dave's total compensation ($USD1.14M) is above average for companies of similar size in the US market ($USD521.92K).
Compensation vs Earnings: Dave's compensation has increased whilst the company is unprofitable.
|Independent Director||6.7yrs||US$111.43k||no data|
|Independent Director||12.7yrs||US$100.05k||no data|
|Independent Director||12.7yrs||US$100.55k||0.017% $5.9k|
|Chairman of the Board||12.7yrs||US$113.18k||1.38% $496.7k|
|Independent Director||12.7yrs||US$91.92k||0.079% $28.5k|
Experienced Board: EVOK's board of directors are seasoned and experienced ( 12.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.9%.
Evoke Pharma, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Evoke Pharma, Inc.
- Ticker: EVOK
- Exchange: NasdaqCM
- Founded: 2007
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$35.863m
- Shares outstanding: 24.23m
- Website: https://www.evokepharma.com
Number of Employees
- Evoke Pharma, Inc.
- 420 Stevens Avenue
- Suite 370
- Solana Beach
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EVOK||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Sep 2013|
|EV0||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 2013|
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/25 01:27|
|End of Day Share Price||2020/02/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.